Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880719 | 0.89 | ALDH1A1 (0.37) | PPIAKMT2A | |
| SCHEMBL4546467 | 0.85 | FKBP1A (0.36) | FKBP1A | |
| SCHEMBL550300 | 0.81 | CTSL (0.42) | CTSLPPIAFKBP1AITGB3ITGA2B | |
| SCHEMBL10028661 | 0.71 | SYK (0.43) | CTSLITGB3ITGA2B | |
| SCHEMBL551499 | 0.68 | KDM4E (0.44) | CTSLFKBP1A | |
| SCHEMBL852502 | 0.67 | OPRM1 (0.47) | KMT2AL3MBTL1 | |
| SCHEMBL4546468 | 0.67 | FKBP1A (0.39) | CTSLFKBP1A | |
| SCHEMBL10028655 | 0.66 | CACNA1B (0.41) | CTSLITGB3ITGA2B | |
| SCHEMBL3718049 | 0.66 | MEN1 (0.48) | KMT2A | |
| SCHEMBL25554839 | 0.65 | TSHR (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9527840-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-06-09 | — | — | US | disclosed |
| US-9278967-B2 | Substituted-quinoxaline-type piperidine compounds and the uses thereof | PURDUE PHARMA L.P. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2015-05-21 | — | — | US | disclosed |
| EP-2280008-B1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS | PURDUE PHARMA LP (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8110602-B2 | Compounds comprising heterocyclic-substituted piperidine for treating pain | PURDUE PHARMA L.P. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159785-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | CTSL 3408/4885PPIA 1535/4885FKBP1A 3075/4885 |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | CTSL 3002/4885PPIA 825/4885FKBP1A 942/4885 |
| US-20150141643-A1 | SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, P2RX5, P2RX3 | CTSL 3408/4885PPIA 1535/4885FKBP1A 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.